trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny,lung02', 'enhertu', 'lung', 'destiny,lung,4']
late-breaking data from destiny-lung02 phase 2 trial of enhertu in patients with previously treated her2 mutant metastatic non-small cell .. $tyo:4568 
Run by investors, for investors.

Real-time:
PRs
Gov. contract awards
Earnings
M&As
FDA approvals
Insider trades
SEC filings
And more

Not investment advice